Could a Dolutegravir-Based Antiretroviral Therapy Lead to Clinical Obesity? A Retrospective Cohort Study Conducted at Hawassa University Comprehensive Specialized Hospital in Hawassa, Sidama, Ethiopia

BACKGROUND: As of April 2019, the dolutegravir (DTG)-based regimen is replacing the efavirenz-based regimen in Ethiopia, mainly due to its superiority in viral load suppression. However, there is a growing concern about this medication-based regimen, the most serious of which is excessive weight gai...

Descripción completa

Detalles Bibliográficos
Autores principales: Eifa, By Aberash, Ketema, Worku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122701/
https://www.ncbi.nlm.nih.gov/pubmed/35603131
http://dx.doi.org/10.1155/2022/2965325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122701/
https://www.ncbi.nlm.nih.gov/pubmed/35603131
http://dx.doi.org/10.1155/2022/2965325

Ejemplares similares